-->

Tag: EGFR-mutated lung cancer therapy

Home / EGFR-mutated lung cancer therapy

Categories

Datopotamab deruxtecan-dlnk is approved by the USFDA for EGFR-mutated non-small cell lung cancer

On June 23, 2025, the Food and Drug Administration conferred accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adults with locally advanced or metastatic epiderm...
egfr-mutated-lung-cancer-therapy

Lazertinib with amivantamab-vmjw is approved by the USFDA for non-small lung cancer

August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, I...
egfr-mutated-lung-cancer-therapy

Scan the code